Intragraft transcriptional profiling of renal transplant patients with tubular dysfunction reveals mechanisms underlying graft injury and recovery

Table 1 Baseline clinical and laboratory characteristics of the renal transplant patients enrolled in this study (n = 33)

Variables	Group 1^a (n = 15)	Group 2^b (n = 18)	p value
Recipient age ± SD, in years	44.9 ± 11.2	45.4 ± 9.9	0.79
Recipient weight ± SD, in kg	67.5 ± 13.8	69.6 ± 14.7	0.35
Recipient male, N (%)	11 (73.3 %)	10 (55.6 %)	0.34
Deceased donors, N (%)	6 (40 %)	6 (33.3 %)	0.69
Haploidentical HLA, N (%)	5 (33.3 %)	10 (55.6 %)	0.20
Time post-transplant ± SD, in months	93.3 ± 35.7	92.4 ± 33.1	0.94
Systemic arterial hypertension, N (%)	13 (86.7 %)	16 (88.9 %)	0.84
Diabetes mellitus, N (%)	2 (13.3 %)	1 (5.6 %)	0.44
Serum creatinine levels ± SD, in mg/dL	1.59 ± 0.28	1.67 ± 0.33	0.46
uRBP levels ± SD, in mg/L	2.79 ± 2.55	2.72 ± 2.24	0.88
Banff classification^c at enrollment	No evidence (3), mild (9), moderate (3), severe (0)	No evidence (2), mild (9), moderate (5), severe (2)	0.64
Banff classification^c after 12 months	No evidence (0), mild (8), moderate (2), severe (2)	No evidence (3), mild (7), moderate (6), severe (1)	0.25

^aGroup 1 patients: initial immunosuppression scheme with cyclosporine, corticosteroids, and azathioprine
^bGroup 2 patients: alternative immunosuppression scheme with reduced levels of cyclosporine and use of mycophenolate mofetil
^cBanff classification: mild, moderate, or severe evidence of interstitial fibrosis and tubular atrophy (IF/TA)

ISSN: 1479-7364